Ketamine + Levetiracetam for Status Epilepticus
(KESETT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.
Who Is on the Research Team?
Jaideep Kapur, MD, PhD
Principal Investigator
University of Virginia
Are You a Good Fit for This Trial?
The KESETT trial is for patients who've had a convulsive seizure lasting over 5 minutes and are still having seizures after getting benzodiazepines. They must be at least 1 year old, weigh more than 10 kg, and have received their last dose of benzodiazepine within the past 5-30 minutes.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Ketamine
Trial Overview
This study tests if adding ketamine to levetiracetam helps control status epilepticus better. Patients will either get levetiracetam with a low or high dose of ketamine, or just levetiracetam alone.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
LEV 60 mg/mL + 1 mg/mL KET
LEV 60 mg/mL + 3 mg/mL KET increasing up to a weight of 75 kg
Levetiracetam (LEV) (60 mg/Kg)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Virginia
Lead Sponsor
Massachusetts General Hospital
Collaborator
University of Michigan
Collaborator
Medical University of South Carolina
Collaborator
Children's National Research Institute
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.